These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8378590

  • 1. Leishmania major infection in BALB/c mice: protection or exacerbation by treatment with different doses of BCG.
    Stefani MM, Müller I, Louis J.
    Res Immunol; 1993 May; 144(4):233-43. PubMed ID: 8378590
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.
    Nahrevanian H, Jafary SP, Nemati S, Farahmand M, Omidinia E.
    Folia Parasitol (Praha); 2013 Feb; 60(1):1-6. PubMed ID: 23539946
    [Abstract] [Full Text] [Related]

  • 3. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
    Rostamian M, Jafari D, Abolghazi M, Farahani H, Niknam HM.
    Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
    [Abstract] [Full Text] [Related]

  • 4. Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice.
    Fortier AH, Mock BA, Meltzer MS, Nacy CA.
    Infect Immun; 1987 Jul; 55(7):1707-14. PubMed ID: 3298065
    [Abstract] [Full Text] [Related]

  • 5. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
    Courret N, Lang T, Milon G, Antoine JC.
    Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
    [Abstract] [Full Text] [Related]

  • 6. The effect of BCG on experimental cutaneous leishmaniasis in mice.
    Weintraub J, Weinbaum FI.
    J Immunol; 1977 Jun; 118(6):2288-90. PubMed ID: 864260
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection.
    Hoseini MH, Moradi M, Alimohammadian MH, Shahgoli VK, Darabi H, Rostami A.
    Parasitol Int; 2016 Apr; 65(2):99-104. PubMed ID: 26518128
    [Abstract] [Full Text] [Related]

  • 8. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge.
    Rivier D, Shah R, Bovay P, Mauel J.
    Parasite Immunol; 1993 Feb; 15(2):75-84. PubMed ID: 8446467
    [Abstract] [Full Text] [Related]

  • 9. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D.
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [Abstract] [Full Text] [Related]

  • 10. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of Leishmania major, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary L. major Infection.
    Schleicher U, Liese J, Justies N, Mischke T, Haeberlein S, Sebald H, Kalinke U, Weiss S, Bogdan C.
    Front Immunol; 2018 Feb; 9():79. PubMed ID: 29459858
    [Abstract] [Full Text] [Related]

  • 11. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P.
    J Immunol; 1991 Nov 01; 147(9):3149-55. PubMed ID: 1833466
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
    Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11473-7. PubMed ID: 8265576
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.
    Liew FY, Li Y, Yang DM, Severn A, Cox FE.
    Immunology; 1991 Oct 15; 74(2):304-9. PubMed ID: 1748478
    [Abstract] [Full Text] [Related]

  • 17. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice.
    Smrkovski LL, Larson CL.
    Infect Immun; 1977 Apr 15; 16(1):249-57. PubMed ID: 873609
    [Abstract] [Full Text] [Related]

  • 18. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.
    Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D.
    Korean J Parasitol; 2007 Jun 15; 45(2):103-9. PubMed ID: 17570972
    [Abstract] [Full Text] [Related]

  • 19. The role of IL-32 in Bacillus Calmette-Guérin (BCG)-induced trained immunity in infections caused by different Leishmania spp.
    Silva MVT, Dos Santos JC, Figueiredo AMB, Teufel LU, Pereira JX, Matos GG, Pinto SA, Netea MG, Gomes RS, Joosten LAB, Ribeiro-Dias F.
    Microb Pathog; 2021 Sep 15; 158():105088. PubMed ID: 34260904
    [Abstract] [Full Text] [Related]

  • 20. IFN-gamma, IL-4, IL-10 and IL-12 gene expression in BCG-Leishmania vaccination of Trypanosoma cruzi-infected mice.
    Araujo Z, Heremans H, Stordeur P, Wissing M, Goldman M, Castes M, Carlier Y.
    Vaccine; 2000 Mar 06; 18(17):1822-9. PubMed ID: 10699330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.